PMCB (PharmaCyte Biotech) Total Liabilities: $16.47 Mil (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.75
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Total Liabilities?

PharmaCyte Biotech PMCB +1.44% 32 Total Liabilities is $16.47 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Total Liabilities for the quarter that ended in Jan. 2026 was $16.47 Mil.

PharmaCyte Biotech's quarterly Total Liabilities increased from Jul. 2025 ($1.52 Mil) to Oct. 2025 ($19.42 Mil) but then declined from Oct. 2025 ($19.42 Mil) to Jan. 2026 ($16.47 Mil).

PharmaCyte Biotech's annual Total Liabilities increased from Apr. 2023 ($0.59 Mil) to Apr. 2024 ($20.39 Mil) but then declined from Apr. 2024 ($20.39 Mil) to Apr. 2025 ($3.28 Mil).

PharmaCyte Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Total Liabilities Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.70 0.59 20.39 3.28

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.58 3.28 1.52 19.42 16.47
PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PharmaCyte Biotech's Total Liabilities for the fiscal year that ended in Apr. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.914+(0+0.363
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.28

Total Liabilities=Total Assets (A: Apr. 2025 )-Total Equity (A: Apr. 2025 )
=55.168-51.891
=3.28

PharmaCyte Biotech's Total Liabilities for the quarter that ended in Jan. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.678+(0+14.793
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.47

Total Liabilities=Total Assets (Q: Jan. 2026 )-Total Equity (Q: Jan. 2026 )
=55.874-39.402
=16.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $16.47 Mil mean?
PharmaCyte Biotech (PMCB) has a Total Liabilities of $16.47 Mil as of Jan. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Total Liabilities too high?
PharmaCyte Biotech's current Total Liabilities is $16.47 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Total Liabilities compare to IMNN and ACXP?
PharmaCyte Biotech's Total Liabilities of $16.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Total Liabilities is $16.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Total Liabilities of $16.47 Mil. The current Total Liabilities is $16.47 Mil. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Total Liabilities is $16.47 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price